Shots:
- Ascletis Pharma has dosed first participants with ASC30 (PO, QD) in its US P-IIa trial for obesity (BMI ≥30kg/m^2) or overweight pts (BMI ≥27kg/m^2 but <30kg/m^2) with ≥1 weight-related comorbidity
- Trial will assess 2 ASC30 formulations (tablets & tablets A1), with pts starting at 1mg & undergoing weekly titrations to maintenance doses of 20 or 40mg (ASC30 tablets) or 20, 40, or 60mg (ASC30 tablets A1), to evaluate mean % body weight change at Wk. 13 as the 1EP; topline data is expected in Q4’25
- ASC30, a small molecule GLP-1R agonist, is developed using an AI-assisted structure-based drug discovery platform & an ultra-long-acting platform, which allow its administrations in both oral tablet & SC injection forms
Ref: PRNewswire | Image: Ascletis Pharma | Press Release
Related News:- Alvotech Partners with Advanz Pharma to Commercialize AVT10 (Biosimilar, Cimzia) in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
